Incannex Healthcare (NASDAQ:IXHL) Trading Down 1.4%

Incannex Healthcare Limited (NASDAQ:IXHLGet Rating)’s share price traded down 1.4% during mid-day trading on Thursday . The company traded as low as $4.15 and last traded at $4.24. 19,295 shares were traded during mid-day trading, a decline of 90% from the average session volume of 195,061 shares. The stock had previously closed at $4.30.

The stock has a 50 day moving average price of $6.66.

An institutional investor recently bought a new position in Incannex Healthcare stock. UBS Group AG bought a new stake in shares of Incannex Healthcare Limited (NASDAQ:IXHLGet Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,757 shares of the company’s stock, valued at approximately $25,000.

Incannex Healthcare Company Profile (NASDAQ:IXHL)

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases.

Recommended Stories

Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Incannex Healthcare (NASDAQ:IXHL) Trading Down 1.4%

Incannex Healthcare Limited (NASDAQ:IXHLGet Rating) shares traded down 1.4% during mid-day trading on Thursday . The stock traded as low as $4.15 and last traded at $4.24. 19,295 shares were traded during trading, a decline of 90% from the average session volume of 195,061 shares. The stock had previously closed at $4.30.

The stock’s 50 day moving average price is $6.66.

An institutional investor recently bought a new position in Incannex Healthcare stock. UBS Group AG bought a new stake in shares of Incannex Healthcare Limited (NASDAQ:IXHLGet Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,757 shares of the company’s stock, valued at approximately $25,000.

Incannex Healthcare Company Profile (NASDAQ:IXHL)

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases.

Recommended Stories

Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.